IL-6 Antibody (YA4917)
(Synonyms: IL6; IFNB2; Interleukin-6; IL-6; B-cell stimulatory factor 2; BSF-2; CTL differentiation factor; CDF; Hybridoma growth factor; Interferon beta-2; IFN-beta-2)IL-6 Antibody (YA4917) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to IL-6.
-
Host:
Mouse
-
Isotype:
IgG
-
Application:
WB, ELISA
-
Reactivity :
Human
-
Formulation:
Supplied in 10mM phosphate buffered saline(pH 7.4) .
-
Conjugation:
Non-conjugated
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
Applications
| Application |
WB
WB: Western Blot
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|
| Dilution Ratio | 1:500 | 1:20000 |
Product Details
IL-6 Antibody (YA4917) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to IL-6.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman
-
Calculated Molecular Weight Predicted band size: 18 kDa;
Recombinant protein within human IL-2 aa 1-153/153.
Protein G affinity purified.
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in 10mM phosphate buffered saline(pH 7.4) .
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Background
-
Function
IL-6 is a pleiotropic cytokine that regulates immune response, acute inflammation, tissue regeneration, metabolism, and stromal activation[1][2]. Mechanistically, IL-6 binds IL-6Rα and recruits gp130, activating JAK/STAT3 signaling and downstream transcriptional programs[1][3]. Disease relevance depends strongly on receptor context: membrane IL-6Rα supports classic signaling, whereas soluble IL-6Rα enables trans-signaling in gp130-expressing cells and drives pro-inflammatory activity[1][4]. Compared with these receptor forms, gp130 is broadly expressed, while IL-6R expression is restricted to selected cells such as hepatocytes and leukocytes, explaining cell-type-selective responsiveness[1]. In vascular endothelial cells, IL-6 trans-signaling induces MCP-1 through coordinated JAK/STAT3 and PI3K/AKT activation[5]. In proliferative vitreoretinopathy models, IL-6 promotes retinal pigment epithelial proliferation and epithelial-mesenchymal transition through JAK1/STAT3 signaling[6]. For experimental intervention, tocilizumab, a humanized anti-IL-6R antibody, blocks IL-6 signaling and improves rheumatoid arthritis outcomes in controlled clinical studies[7][8].
-
Subcellular Localization
Secreted
-
Expression
Tissue_specificity:Produced by skeletal muscle
Induction:Plasma levels are highly increased upon exercise, due to enhanced production by contracting skeletal muscles. Up-regulated by coagulation factor Xa (F10) in PAR-1 (F2R) -dependent manner in cardiac fibroblasts (PubMed:34831181) -
Subunit
Component of a hexamer of two molecules each of IL6, IL6R and IL6ST; first binds to IL6R to associate with the signaling subunit IL6ST (PubMed:12829785). Interacts with IL6R (via the N-terminal ectodomain); this interaction may be affected by IL6R-binding with SORL1, hence decreasing IL6 cis signaling (PubMed:28265003). Interacts with SORL1 (via the N-terminal ectodomain); this interaction leads to IL6 internalization and lysosomal degradation (PubMed:28265003). May form a trimeric complex with the soluble SORL1 ectodomain and soluble IL6R receptor; this interaction might stabilize circulating IL6, hence promoting IL6 trans signaling (PubMed:28265003)
-
SwissProt ID
-
Synonyms
IL6; IFNB2; Interleukin-6; IL-6; B-cell stimulatory factor 2; BSF-2; CTL differentiation factor; CDF; Hybridoma growth factor; Interferon beta-2; IFN-beta-2
Documentation
References
[1]. Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237-47. doi: 10.7150/ijbs.4989. Epub 2012 Oct 24. PMID: 23136552; PMCID: PMC3491447. et al. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci. 2012;8(9):1237-47. [Content Brief]
[2]. Danese S, et al. Interleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases. Gut. 2010 Feb;59(2):149-51. [Content Brief]
[3]. Reeh H, et al. Response to IL-6 trans- and IL-6 classic signalling is determined by the ratio of the IL-6 receptor α to gp130 expression: fusing experimental insights and dynamic modelling. Cell Commun Signal. 2019 May 17;17(1):46. [Content Brief]
[4]. Maes M, et al. Targeting classical IL-6 signalling or IL-6 trans-signalling in depression? Expert Opin Ther Targets. 2014 May;18(5):495-512. [Content Brief]
[5]. Zegeye MM, et al. Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells. Cell Commun Signal. 2018 Sep 5;16(1):55. [Content Brief]
[6]. Chen X, et al. Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway. Mol Vis. 2020 Jul 29;26:517-529. [Content Brief]
[7]. Ohsugi Y, et al. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2008 May;8(5):669-81. [Content Brief]
[8]. Emery P, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008 Nov;67(11):1516-23. [Content Brief]
Powered by Bioz
